2 weeks Ago By ABMN Staff
American Century Companies Inc. decreased its stake in shares of Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA – Free Report ) by 40.
0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 203,038 shares of the biotechnology company’s stock after selling 135,478 shares during the quarter. American Century Companies Inc.
owned about 0.07% of Iovance Biotherapeutics worth $1,628,000 at the end of the most recent reporting period. A number of other large investors have also recently made changes to their positions in IOVA.
Headlands Technologies LLC purchased a new stake in Iovance Biotherapeutics in the 2nd quarter worth approximately $129,000. Daiwa Securities Group Inc. boosted its holdings in Iovance Biotherapeutics by 754.
0% during the second quarter. Daiwa Securities Group Inc. now owns 8,813 shares of the biotechnology company’s stock worth $71,000 after buying an additional 7,781 shares in the last quarter.
Choreo LLC acquired a new stake in Iovance Biotherapeutics during the second quarter valued at $116,000. Quest Partners LLC increased its holdings in Iovance Biotherapeutics by 1,237.7% in the second quarter.
Quest Partners LLC now owns 5,003 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 4,629 shares in the last quarter. Finally, Pier 88 Investment Partners LLC raised its position in shares of Iovance Biotherapeutics by 155.8% in the second quarter.
Pier 88 Investment Partners LLC now owns 58,580 shares of the biotechnology company’s stock worth $470,000 after acquiring an additional 35,680 shares during the period. 77.03% of the stock is owned by hedge funds and other institutional investors.
Iovance Biotherapeutics Stock Performance NASDAQ:IOVA opened at $9.61 on Monday. Iovance Biotherapeutics, Inc.
has a one year low of $3.21 and a one year high of $18.33.
The stock has a market cap of $2.69 billion, a PE ratio of -5.34 and a beta of 0.
63. The stock has a 50 day moving average price of $9.90 and a 200 day moving average price of $10.
44. Analyst Upgrades and Downgrades Several brokerages have commented on IOVA. StockNews.
com raised Iovance Biotherapeutics to a “sell” rating in a report on Monday, August 12th. HC Wainwright reissued a “buy” rating and issued a $32.00 price target on shares of Iovance Biotherapeutics in a research note on Monday, August 12th.
Piper Sandler lowered shares of Iovance Biotherapeutics from an “overweight” rating to a “neutral” rating and cut their price target for the stock from $19.00 to $10.00 in a report on Monday, July 29th.
Finally, JMP Securities decreased their price objective on shares of Iovance Biotherapeutics from $25.00 to $23.00 and set a “market outperform” rating on the stock in a report on Thursday, June 20th.
One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Iovance Biotherapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $23.
00. View Our Latest Research Report on IOVA About Iovance Biotherapeutics ( Free Report ) Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.
See Also Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
